Moclobemide: Evolution, pharmacodynamic, and pharmacokinetic properties

CNS Drug Reviews

Volumn 8, Issue 3, 2002, Pages 283-308

  Bonnet, Udo ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Anxiety; Depression; MAO inhibitors; Moclobemide

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BENZAMIDE DERIVATIVE; BETA ADRENERGIC RECEPTOR; BROFAROMINE; CLORGYLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUCOCORTICOID RECEPTOR; HARMAN; HISTAMINE H1 RECEPTOR; IPRONIAZID; ISOCARBOXAZID; KAPPA OPIATE RECEPTOR; LAZABEMIDE; MINERALOCORTICOID RECEPTOR; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MU OPIATE RECEPTOR; MUSCARINIC RECEPTOR; PARGYLINE; PHENELZINE; SELEGILINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SIGMA OPIATE RECEPTOR; TOLOXATONE; TRANYLCYPROMINE; TYRAMINE; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ANXIETY NEUROSIS; AREA UNDER THE CURVE; COGNITION; DEPRESSION; DRIVING ABILITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENZYME INHIBITION; FOOD DRUG INTERACTION; HUMAN; LIVER TOXICITY; MOUSE; NEUROENDOCRINE SYSTEM; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; ORTHOSTATIC HYPOTENSION; RAT; REVIEW; SEIZURE; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SLEEP; TRANQUILIZING ACTIVITY;

EID: 0036750734     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2002.tb00229.x     Document Type: Review

References (182)

1. 2 imidazoline-preferring receptors. Br J Pharmacol 1995;114:837-845.
2. Allain H, Lieury A, Brunet-Bourgin F, et al. Antidepressants and cognition: Comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992;106:S56-S61.
3. Amrein R, Martin JR, Cameron AM. Moclobemide in patients with dementia and depression. Adv Neurol 1999;80:509-519.
4. Anand R, Wesnes KA. Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. Adv Neurol 1990;51:261-268.
5. Ananth J, Luchins D. A review of combined tricyclic and MAOI therapy. Comprehensive Psychiatry 1977;18:221-230.
6. Arai R, Horiike K, Hasegawa Y. Dopamine-degrading activity of monoamine oxidase is not detected by histochemistry in neurons of the substantia nigra pars compacta of the rat. Brain Res 1998;812:275-278.
7. 11C] deprenyl. J Neurochem 1987;49:522-527.
8. Bach AJB, Lan NC, Johnson DL, et al. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 1988;85:4934-4938.
9. a. Baker GB, Urichuk LJ, McKenna KF, et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999;19411-426.
10. 11C-Harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies. Nucl Med Biol 1997;24:287-293.
11. Bergström M, Westerberg G, Németh G, et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography. Eur J Clin Pharmacol 1997;52:121-128.
12. Berlin I, Zimmer C, Coumot A, et al. Determination and comparison of the pressure effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 1989;46:344-351.
13. Berlin I, Zimmer R, Thiede HM, et al. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, an assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol 1990;30:805-816.
14. Berlin I, Said S, Spreux-Varoquaux O, et al. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 1995;38:756-761.
15. Biek PR, Antonin K-H. Tyramine potentiaton during treatment with MAO inhibitors: brofaromine, and moclobemide vs. irreversible inhibitors. J Neural Transm 1989;28(Suppl):21-31.
16. Bjartmar L, Johansson IM, Ross SB, et al. Selective effects on NGFI-A, MR, GR, and NGFI-B hippocampal mRNA expression after chronic treatment with different subclasses of antidepressants in the rat. Psychopharmacology 2000;151:7-12.
17. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991;11:55-59.
18. Blois R, Gaillard JM. Effects of moclobemide on sleep in healthy human subjects. Acta Psychiatr Scand 1990:82(Suppl 360):73-75.
19. Bonnet U, Wiemann M. Ammonium prepulse: Effects on intracellular pH and bioelectric activity of CA3-neurones in guinea-pig hippocampal slices. Brain Res 1999;840:16-22.
20. Bonnet U, Leniger T, Wiemann M. Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices - implication for its neuroprotective properties. Neuropharmacology 2000;39:2067-2074.
21. Bonnet U, Wiemann M, Bingmann D. Intracellular pH modulates spontaneous and epileptiform bioelectric activity of hippocampal CA3-neurones. Eur Neuropsychopharmacol 2000;97:97-103.
22. Bonnet U, Büsselberg D, Wiemann M. MAO-inhibition is associated with a modest neuronal acidification. Pharmacopsychiatry 2001;34:165.
23. Bonnet U. Moclobemide: Therapeutic Use and Clinical Studies. CNS Drug Rev; In press.
24. a. Bonnet U, Bingmann D, Leniger T, et al. Valproate acidifies hippocampal CA3 neurones - a novel mode of action. Eur Neuropsychopharmacol 2002;12:279-285.
25. Bousquet P, Feldmann J. Drugs acting on imidazoline receptors. A review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection. Drugs 1999;58:799-812.
26. Brodie BB, Bickel MH, Sulser F. Desimipramine, a new type of antidepressant drug. Med Exp 1961;5:454-458.
27. Burkard WP, Bonetti EP, Da Prada M, et al. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989;248:391-399.
28. Burrows GD, Da Prada M (eds). Reversible MAO-A inhibitors as antidepressants - basic advances and clinical perspectives, J Neural Transm 1989;28:1-103.
29. a. Cocio S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998;34:281-302
30. Callingham BA, Ovens RS. Some in vitro effects of moclobemide and other MAO inhibitors on responses to sympathomimetic amines. J Neural Transm 1987;26:17-29.
31. Cao Danh H, Strolin Benedetti M, et al. Differential changes in monoamine oxidase A and B activity in aging rat tissues. In: Tripton KF, Dostert P, Strolin Benedetti M, Eds. Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press, 1984:301-317.
32. Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Progr Drug Res 1992;38:171-297.
33. Codoz D, Porchert HC, Dayer P. Central analgesic effects of desimipramine, fluvoxamine, and moclobemide after single oral dosing: A study in healthy volunteers. Clin Pharmacol Ther 1993;54:339-344.
34. Colzi A, d'Agostini F, Cesura AM, et al. Brain microdialysis in rats: A technique to reveal competition in vivo between endogeneous dopamine and moclobemide, a RIMA antidepressant. Psychopharmacology 1992;106: S17-S20.
35. Crane GE. Iproniazid (Marsilin®) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psych Res Rep Am Psych Ass 1957;8:142-152.
36. Da Prada, M, Zürcher G, Wüthrich I, et al. On tyramine, food, beverages, and reversible MAO inhibitor moclobemide. J Neural Transm 1988;26(Suppl):31-36.
37. Da Prada M, Kettler R, Keller HH, et al. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989;248:400-414.
38. Da Prada M, Kettler R, Burkhard WP, et al. Some basic aspects of reversible inhibitors of monoamie oxidase-A. Acta Psychiatr Scand 1990;82(Suppl 360):7-12.
39. Da Prada M, Zürcher G. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology 1992;106:S32-S34.
40. Da Prada, Pieri L, Cesura AM, et al. The pharmacology of moclobemide. Rev Contemp Pharmacother 1994;5:1-18
41. DeLorenzo RJ, Dashefsky LH. Anticonvulsants. Handb Neurochem 1985;9:363-403.
42. Dingemanse J, Kom A, Pfefen J-P, et al. Biochemical effects of high single doses of moclobemide in man: Correlation with plasma concentrations. Psychopharmacology 1992;106:S46-S48.
43. Dingemanse J, Berlin I, Payan C, et al. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychomotor performance in healthy subjects. Psychopharmacology 1992;106:S68-S70.
44. Dingemanse J, Wood N, Guentert T, et al. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology 1998;140:164-172.
45. Dingemanse J, Wallnöfer A, Gieschke R, et al. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of the "serotonin syndrome." Clin Pharmacol Ther 1998;63:403-413.
46. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
47. Eisenhofer G, Goldstein DS, Ropchak TG, et al. Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Auton Nerv Syst 1988;24:1-14.
48. Eisenhofer G, Bush JE, Cannon RI, et al. Plasma dihydroxyphenylalanine and total body and regional noradrenergic activity in humans. J Clin Endocrinol Metab 1989;68:247-255.
49. Eisenhofer G, Pecorella W, Pacak K, et al. The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. J Nerv Auton Syst 1994;50:93-107.
50. Ekblom J, Tottmar O, Oreland L. Cytoprotection by deprenyl and tocapone in a cell culture model of cerebral ischemia. Pharmacol Toxicol 1998;83:194-199.
51. Fairweather DB, Hindmarch I. The behavioural toxicity of reversible inhibitors of monoamine oxidase A: Laboratory and clinical investigations. J Clin Psychopharmacol 1995;15(Suppl 2):68S-75S.
52. Finberg JP, Youdim MBH. Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transm 1987;26:11-16.
53. Finberg JPM. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Acta Psychiatr Scand 1995;91(Suppl 386):8-13.
54. Fitton A, Faulds D, Goa KL. Moclobemide - a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992;43:561-596.
55. Fitzgerald LW, Kaplinsky L, Kimelberg HK. Serotonin metabolism by monoamine oxidase in rat primary astrocyte cultures. J Neurochem 1990;55:2008-2014.
56. Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarrete smokers. Proc Natl Acad Sci USA 1996;93:14065-14069.
57. Frazer A. Antidepressants. J Clin Psychiatry 1997;58(Suppl 6):9-25.
58. Freeman H. Moclobemide. Lancet 1993;342:1528-1532.
59. Fritze J, Laux G, Sofic E, et al. Plasma moclobemide and metabolites: Lack of correlation with clinical response and biogenic amines. Psychopharmacology 1989;99:252-256.
60. Fulton B, Benfield P. Moclobemide - an update of its pharmacological properties and therapeutic use. Drugs 1996;52:450-474.
61. Galderisi S, Mucci A, Bucci P, et al. Influence of moclobemide on cognitive functions of nine depressed patients: Pilot trial with neurophysiological and neuropsychological indices. Neuropsychobiology 1996;33:48-58.
62. Galva MD, Bondiolotti GP, Olasmaa M, et al. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex. J Neural Transm 1995;101:3-94.
63. Geschke R, Koerner J, Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. J Chromatogr 1987;420:110-120.
64. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: Analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995;17:36-46.
65. Gieschke R, Schmidt-Burgk W, Amrein R. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. J Neural Transm 1987;26:97-104.
66. Gleiter CH, Nilsson E, Antonin KH, et al. Effect of MAO inhibitors (brofaromine, clorgyline and moclobemide) on human platelet MAO-B activity. Clin Pharmacol Ther 1990;47:165.
67. Goldina OA, Valdman AV. Anticonvulsant effect of some psychotropic drugs and benzamide derivatives with regard to antimonoamine oxidase activity. Eur Neuropsychopharmacol 1994;4:446-447.
68. Goodnick PJ. Pharmacokinetic optimization of therapy with newer antidepressants. Clin Pharmacokinet 1994;27:307-330.
69. Gram LF, Brosen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993;35:649-652.
70. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. Clin Pharmacol Ther 1995;57:670-677.
71. GriebeI G, Perrault G, Sanger DJ. Behavioural profiles of the reversible monoamine-oxidase inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and antipanic drugs. Psychopharmacology 1997;131:180-186.
72. Guentert TW, Banken L, Hilton S, et al. Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol 1995;15(Suppl 2):84S-94S.
73. Haefely W, Burkard WP, Cesura AM, et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 1992;106:S6-S14.
74. Haefely W, Burkard WP, Cesura A, et al. Pharmacology of moclobemide. Clin Neuropharmacol 1993;16(Suppl 2):S8-S18.
75. Härtter S, Dingemanse J, Baier D, et al. The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropharmacol 1996;6:225-230.
76. Haring C, Baier D, Herberg KW. Verkehrstüchtigkeit unter Moclobemid. Münchener Med Wochenschrift 1995;137:217-222.
77. Harro J, Oreland L. Depression as a spreading neuronal adjustment disorder. Eur Neuropsychopharmacol 1996;6:207-223.
78. Hartley Z, Dubinski JM. Changes in intracellular pH associated with glutamate excitotoxicity. J Neurosci 1993;13:4690-4699.
79. Hasan F, McCrodden JM, Kennedy NP, et al. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm 1988;26(Suppl):1-9.
80. Hida T, Arai R. Monoamine oxidase activity in noradrenaline neurons of locus coeruleus of the rat. A double-labeling histochemical study. Brain Res 1998;814:209-212.
81. Himmelhoch JM. Monoamine oxidase inhibitors. In: Kaplan HI, Sadock BJ, Eds. Comprehensive textbook of psychiatry/VI. Vol. 2. Sixth edition. Baltimore: Williams & Wilkins, 1995:2038-2054.
82. Hindmarch I, Kerr J. Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 1992;106:S49-S55.
83. Hindmarch I, Kerr JS, Fairweather DB. The effects of moclobemide on psychomotor performance and cognitive function in the elderly. Dementia 1992;3:355-359.
84. Hoff P, Golling H, Kampfhammer HP, et al. Cimoxatone and moclobemide, two new MAO inhibitors: Influence in sleep parameters in patients with major depressive disorder. Pharmacopsychiatry 1986;19:249-250.
85. Holford NHG, Guenter TW, Dingsemanse J, et al. Monoamine oxidase A: Pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin Pharmacol 1994;37:433-439.
86. Holsboer F. Neuroendocrinology of mood disorders. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The fourth generation of progress. New York: Raven Press, 1995:957-969.
87. Hoskins JM, Gross AS, Shenfield GM, et al. High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurements of moclobemide and two of its metabolites in plasma. J Chromatogr B Biomed Sci Appl 2001;754:319-326.
88. 3H]rilmenidine binding sites in rat brain. J Auton Nerv Syst 1988;72:129-136.
89. a. Hough CJ, Chuang D-M. The mitochondrial hypothesis of bipolar disorder. Bipolar Disord 2000;2:145-147.
90. Itzhak Y, Stein I, Zhang S-H, et al. Binding of s-ligands to C57BL/6 mouse brain membranes: Effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of s-receptor subtypes. J Pharmacol Exp Ther 1991;257:141-148.
91. Jakobs BL. Animal behavior model for study central serotonergic synapses. Life Sci 1976;19:777-786.
92. Jauch R, Griesser E, Oesterhelt G, et al. Biotransformation of moclobemide in humans. Acta Psychiatr Scand 1990;82(Suppl 360):87-90.
93. Juruena MF, Pires ML, Calil HM. Moclobemide effects on prolactin plasma levels in healthy individuals: The hormonal increase induced by a single dose is maintained during a 4-week period of drug intake. Int Clin Psychopharmacol 1997;12:317-321.
94. Kaila K. Ionic basis of GABAA receptor channel function in the nervous system. Progr Neurobiol 1994;42:489-537.
95. a. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000;2:180-190.
96. Kettler R, Da Prada M, Burkard WP. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand 1990;82(Suppl 360):101-102.
97. 1-adrenergic and dopaminergic receptors in rat brain. Neurosci Lett 1990;108:189-194.
98. Kochersberger LM, Parker EL, Siciliano M, et al. Assignment of genes for human monoamine oxidase Aand B to X chromosome. J Neurosci Res 1986;16:601-619.
99. Korn A, Da Prada M, Faffesberg W, et al. Tyramine pressure effect in man: Studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm 1988;26(Suppl):57-71.
100. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition of monoamine oxidase by moclobemide: Effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-255.
101. Lalies MD, Hibell A, Hudson AL, et al. Inhibition of central monoamine oxidase by imidazoline 2 site-selective ligands. Ann NY Acad Sci 1999;881:115-117.
102. Laux G, Volz H-P, Möller H-J. Newer and older monoamine oxidase inhibitors. A comparative profile. CNS Drugs 1995;3:145-158.
103. Lavie P, Aharon-Peretz J, Klein F, et al. Sleep quality in geriatric depressed patients: Comparison with elderly demented patients and normal controls and the effects of moclobemide. Dementia 1992;3:360-366.
104. 3H]quinpirole binding in brain by monoamine oxidase inhibitors: Evidence for a potential novel binding site. J Pharmacol Exp Ther 1996;278:145-153.
105. Lipper S, Murphy DL, Slater S, et al. Comparative behavioural effects of clorgyline and pargyline in man: A preliminary investigation. Psychopharmacology 1979;62:123-128.
106. Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update of drug interactions. Drug Safety 1996;14:219-227.
107. Lorenz HP, Harvey J, Wright L. Moclobemide exhibits neuroprotective effects in hypoxic rat brain. In: Krieglstein J, Oberpichler H, Eds. Pharmacology of cerebral ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1990:477-484.
108. Maguire K, Pereira A, Tiller J. Moclobemide pharmacokinetics in depressed patients: Lack of age effect. Hum Psychopharm 1991;6:249-252.
109. Magyar K, Szende B, Lengyel J, et al. The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm 1998;52(Suppl):109-123.
110. Mann JJ, Stanley M. Postmortem monoamine oxidase enzyme kinetics in the frontal cortex of suicide victims and controls. Acta Psychiatr Scand 1984;69:135-139.
111. Markianos M, Alevizos V, Stefanis C. Plasma sex hormones and urinary biogenic amine metabolites during treatment of male depressed patients with the monoamine oxidase inhibitor moclobemide. Neuroedocrinol Lett 1991;13:49-55.
112. Marley E, Wozniak KM. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine reuptake inhibitors. Psychol Med 1983;13:735-749.
113. Martin JR, Schaffner R, Rumennik L. Cognitive performance enhancing effects of the reversible MAO inhibitor moclobemide. In: Wurtman RJ, Corkin S, Growdon JH, Ritter-Walker E, Eds. Alzheimer's disease. Cambridge: Center for Brain Sciences and Metabolism Charitable Trust, 1989:689-694.
114. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995;29:292-332.
115. 1-Adrenoreceptor-mediated responses in the lateral geniculate nucleus are enhanced by chronic antidepressant tratment. Eur J Pharmacol 1981;74:27-35.
116. Möller H-J, Laux G, Müller WE. Moclobemide. Psychopharmakotherapie 1994;4(Suppl 2):3-37
117. Monti JM, Alterwain P, Monti D. The effect of moclobemide on nocturnal sleep of depressed patients. J Affect Disord 1990;20:201-208.
118. Moreau J-K, Jenck F, Martin JR, et al. Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 1992;2:43-49.
119. Moreau J-K, Jenck F, Martin JR, et al. Effects of moclobemide, a new generation reversible MAO-A inhibitor, in a novel model of depression. Pharmacopsychiatry 1993;26:30-33.
120. Mori S, Zanardi R, Popoli M, et al. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide. J Psychiatr Res 1998;32:111-115.
121. Morell V. Evidence found for possible "aggression gene." Science 1993;260:1722-1723.
122. Montkowski A, Barden N, Wotjak C, et al. Long-term antidepressant tratment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 1995;7:841-845.
123. Naranjo C. Psychotherapeutic properties of harmala alkaloids. In: Efron D, Holmstedt B, Kline N, Eds. Ethnopharmacologic search for psychoactive drugs. New York: Raven Press, 1979:385-396.
124. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP dependent protein kinase in rat frontal cortex. J Neurochem 1989;53:1644-1647.
125. Nestler EJ. Antidepressant treatment in the 21st century. Biol Psychiatry 1998;44:526-533.
126. Nowakowska E, Chodera A, Kus K, et al. Anxioloytic and memory improving effects of moclobemide. Arzneimittelforschung 1998;48:625-628.
127. 3H]-idazoxan binding sites in rat brain. Br J Pharmacol 1993;108:597-603.
128. Ordway GA, Farley JT, Dilley GE, et al. Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res 1999;847:71-79.
129. 11C-L-deprenyl. J Neural Transm 1990;32:55-59.
130. Pancheri P, Delle-Chiaie R, Donnini M, et al. Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: A controlled comparative study versus imipramine. Clin Neuropharmacol 1994;17(Suppl 1):S58-S73.
131. Parini A, Moudanous CG, Pizzinat N, et al. The elusive family of imidazoline binding sites. Trends Pharmacol Sci 1996;17:13-16.
132. Perez J, Tinelli D, Bianchi E, et al. cAMP binding proteins in the rat cerebral cortex after administration of selective 5-HT and NE reuptake blockers with antidepressant activity. Neuropsychopharmacology 1991;4:57-64.
133. 1-imidazoline receptors in mood disorders. Ann NY Acad Sci 1995;763:510-519.
134. Pletscher A, Besendorf H, Bächthold HP, et al. Über pharmakologische Beeinflussung des Zentralnerven-systems durch kurzwirksame Monoaminoxydasehemmer aus der Gruppe der Harmala-Alkaloide. Helv Physiol Acta 1959;17:202-214.
135. Pons G, Schoerlin MP, Tam YK, et al. Moclobemide excretion in human breast milk. Br J Clin Pharmacol 1990;29:27-31.
136. Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336.
137. Porsolt RD. Behavioural despair. In: Enna SJ, Malick JB, Richelson E, Eds. Antidepressants: Neurochemical, behavioural and clinical perspectives. New York: Raven Press, 1981:121-139.
138. Potter WZ, Murphy DL, Wehr TA, et al. Clorgyline. A new treatment for patients with refractory rapid-cycling disorder. Arch Gen Psychiatry 1982;39:505-510.
139. Priest RG (ed.). The treatment of depression in the 1990s - a focus on moclobemide. Acta Psychiatr Scand 1990;82(Suppl 360):39-108.
140. a. Priest RG, Schmid-Burgk W. Moclobemide in the treatment of depression. Rev Contemp Pharmacother 1994;5:35-43.
141. Raaflaub J, Haefelfinger P, Trautmann KH. Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. Arzneimittelforschung 1984;34:80-82.
142. Radat F, Berlin I, Spreux-Varoquaux O, et al. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study. Psychopharmacology 1996;127:370-376.
143. Ramaekers JG, Swijgman HF, O'Hanlon JF. Effects of moclobemide and mianserin on highway driving, psychomotor performance and subjective parameters, relative to placebo. Psychopharmacology 1992;106:S62-S67.
144. Reul JMHM, Stec I, Söder M, et al. Chronic treatment of rats with the antidepressant amitryptiline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993;133:312-320.
145. Reul JMHM, Labeur MS, Grigoriadis DE, et al. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994;60:509-519.
146. Robitzek EH, Selikoff IJ. Hydrazine derivates of isonicotinic acid (Rimifon, Marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis. Am Rev Tuberc 1952;65:402-428.
147. Rommelspacher H, May T, Salewski B. Harman (1-methyl-β- carboline) is a natural inhibitor of monoamine oxidase A in rats. Eur J Pharmacol 1994;252:51-59.
148. Saura M, Marti J, Kettler R, et al. Molecular anatomy of MAO-A and MAO-B. J Neural Transm 1990;Suppl 32:49-53.
149. Saura J, Bleuel Z, Ulrich J, et al. Molecular neuroanatomy of human monoamine oxidase A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 1996;70:755-774.
150. Schreiber S, Getslev V, Weizman A, et al. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett 1998;253:183-186.
151. Seiler N, al-Therib MJ, Kataoka K. Formation of GABA from putrescine in the brain of fish (Salmo irideus Gibb.). J Neurochem 1973;20:699-708.
152. Scheinin M, Koulu M, Vakkuri O, et al. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:73-82.
153. Scherschlicht R, Polc P, Schneeberger J, et al. Selective suppression of rapid eye movement sleep (REMs) in rats by typical and atypical antidepressants. In: Costa E, Racagni G, Eds. Typical and atypical antidepressants. New York: Raven Press, 1982:359-364.
154. Schoerlin M-P, Mayersohn M, Korn A, et al. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: Single and multiple dosing in normal subjects. Clin Pharmacol Ther 1987;42:395-404.
155. Schoerlin M-P, Da Prada M. Species-specific biotransformation of moclobemide: A comparative study in rats and humans. Acta Psychiatr Scand 1990;82(Suppl 360):108-110.
156. Schoerlin M-P, Horber FF, Frey FJ, et al. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol 1990;30:272-284.
157. Sherif F, Marcusson J, Oreland L. Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims. Eur Arch Psych Clin Neurosci 241:139-144.
158. Shih JC. Molecular basis of human MAO A and B. Neuropsychopharmacology 1991;4:1-7.
159. Silver H, Youdim MBH. MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine. Eur Neuropsychopharmacol 2000;10:125-128.
160. Simpson GM, Gratz SS. Comparison of the pressure effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther 1992;52:286-291.
161. Smith GAM, Brett CL, Church J. Effects of noradrenaline on intracellular pH in acutely dissociated adult rat hippocampal neurons. J Physiol 1998;512:487-505.
162. Stabl M, Bizière W, Schmid-Burgk W, et al. Review of comparative clinical trials. Moclobemide vs. tricyclic antidepressants and vs. placebo in depressive states. J Neural Transm 1989;Suppl 28:77-89.
163. Steckler T, Rammes G, Sauvage M, et al. Effects of the monoamine oxidase A inhibitor moclobemide on hippocampal plasticity in GR-impaired transgenic mice. J Psychiat Res 2001;35:29-42.
164. Steiger A, Holsboer F, Benkert O. Long term studies on the effect of tricyclic antidepressants and selective MAO-A inhibitors on sleep, nocturnal penile tumescence and hormonal secretion in normal controls. In: Koella WP, Ed. Sleep. Stuttgart: Verlag, 1988:335-337.
165. Stern G. Neuroprotection by selegiline and other MAO inhibitors. J Neural Transm 1998;52(Suppl):99-107.
166. Stoeckel K, Pfefen JP, Mayersohn M, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand 1990;82(Suppl 360):94-97.
167. Strolin-Benedetti M, Dostert P. Monoamine oxidase, brain aging and degenerative diseases. Biochem Pharmacol 1989;38:555-561.
168. Strolin-Benedetti M, Kettler R, Marrai P, et al. The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain. J Neural Transm 1990;2:239-248.
169. Takahashi K-I, Copenhagen DR. Modulation of neuronal function by intracellular pH. Neurosci Res 1996;24:109-116.
170. Tiller JWG, Bouwer C, Behnke K. Moclobemide for anxiety disorders: A focus on moclobemide for panic disorder. Int Clin Psychopharmacol 1997;12(Suppl 6):S27-S30.
171. Trendelenburg U, Langeloh A, Bönisch H. Mechanism of indirectly acting sympathomimetic amines. Blood Vessels 1987;24:261-270.
172. Trudeau LE, Parpura V, Haydon PG. Activation of neurotransmitter release in hippocampal nerve terminals during recovery from intracellular acidification. J Neurophysiol 1999;81:2627-2635.
173. Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 1975;257:495-496.
174. Vignes M, Blanc E, Guiramand J, et al. A modulation of glutamate-induced phosphoinositide breakdown by intracellular pH changes. Neuropharmacology 1996;45:1595-1604.
175. Von Korff RW. Monoamine oxidase: unanswered questions. In: Singer TP, von Korff RW, Murphy DL, Eds. Monoamine oxidase: Structure, function and altered functions. New York: Academic Press, 1979:1-7.
176. Walaas, Greengard P. Protein phosphorylation and neuronal function. Pharmacol Rev 1991;43:299-334.
177. Waldmeier PC. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J Neural Transm 1987;23(Suppl):55-72.
178. Wesnes KA, Simpson PM, Christmas L, et al. The effects of moclobemide on cognition. J Neural Transm 1989;28(Suppl):91-102.
179. Westlund KN, Denny RM, Kochersberger LM, et al. Distinct monoamine oxidase A and B populations in primate brain. Science 1985;230:181-183.
180. Willner P. Animal models as simulations of depression. TIPS 1991;12:131-136.
181. Youdim MBH, Finberg JPM, Tipton KF. Monoamine oxidase. In: Trendelenburg U, Weiner N, Eds. Catecholamines I. Berlin: Springer, 1988:119-192.
182. Young JD, Cohen DJ, Waldo MD, et al. Platelet monoamine oxidase activity in children and adolescents with psychiatric disorders. Schizophren Bull 1980;6:324-333.